112 related articles for article (PubMed ID: 21764450)
21. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS).
Cantù Rajnoldi A; Fenu S; Kerndrup G; van Wering ER; Niemeyer CM; Baumann I;
Ann Hematol; 2005 Jul; 84(7):429-33. PubMed ID: 15838669
[TBL] [Abstract][Full Text] [Related]
22. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
23. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
[TBL] [Abstract][Full Text] [Related]
24. A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients.
Boutault R; Peterlin P; Boubaya M; Sockel K; Chevallier P; Garnier A; Guillaume T; Le Bourgeois A; Debord C; Godon C; Le Bris Y; Theisen O; Kroschinsky F; Moreau P; Béné MC; Platzbecker U; Eveillard M
Br J Haematol; 2018 Dec; 183(5):736-746. PubMed ID: 30406952
[TBL] [Abstract][Full Text] [Related]
25. Picking up myelodysplastic syndromes and megaloblastic anemias on peripheral blood: use of NEUT-X and NEUT-Y in guiding smear reviews.
Goel S; Sachdev R; Gajendra S; Jha B; Sahni T; Dorwal P; Srivastava C; Tiwari AK; Sood N; Gupta S; Raina V; Vaid AK
Int J Lab Hematol; 2015 Apr; 37(2):e48-51. PubMed ID: 25132616
[No Abstract] [Full Text] [Related]
26. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.
Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM
Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866
[TBL] [Abstract][Full Text] [Related]
27. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
[TBL] [Abstract][Full Text] [Related]
28. Reference range evaluation of complete blood count parameters with emphasis on newer research parameters on the complete blood count analyzer Sysmex XE-2100.
Sehgal KK; Tina D; Choksey U; Dalal RJ; Shanaz KJ
Indian J Pathol Microbiol; 2013; 56(2):120-4. PubMed ID: 24056647
[TBL] [Abstract][Full Text] [Related]
29. The utility of the Sysmex XE-2100 analyzer's NEUT-X and NEUT-Y parameters for detecting neutrophil dysplasia in myelodysplastic syndromes.
Furundarena JR; Araiz M; Uranga M; Sainz MR; Agirre A; Trassorras M; Uresandi N; Montes MC; Argoitia N
Int J Lab Hematol; 2010 Jun; 32(3):360-6. PubMed ID: 19906272
[TBL] [Abstract][Full Text] [Related]
30. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
[TBL] [Abstract][Full Text] [Related]
31. Copper deficiency: an important consideration in the differential diagnosis of myelodysplastic syndrome.
Fong T; Vij R; Vijayan A; DiPersio J; Blinder M
Haematologica; 2007 Oct; 92(10):1429-30. PubMed ID: 18024379
[TBL] [Abstract][Full Text] [Related]
32. Platelet mass has prognostic value in patients with myelodysplastic syndromes.
Bowles KM; Warner BA; Baglin TP
Br J Haematol; 2006 Oct; 135(2):198-200. PubMed ID: 16939490
[TBL] [Abstract][Full Text] [Related]
33. Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes.
Hirano T; Hiratsuka N; Iwahori T; Oka K; Wakasugi K
Res Commun Mol Pathol Pharmacol; 2003; 113-114():315-28. PubMed ID: 15686130
[TBL] [Abstract][Full Text] [Related]
34. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders.
Lorand-Metze I; Ribeiro E; Lima CS; Batista LS; Metze K
Leuk Res; 2007 Feb; 31(2):147-55. PubMed ID: 16750852
[TBL] [Abstract][Full Text] [Related]
35. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis.
Rossi E; Basso U; Celadin R; Zilio F; Pucciarelli S; Aieta M; Barile C; Sava T; Bonciarelli G; Tumolo S; Ghiotto C; Magro C; Jirillo A; Indraccolo S; Amadori A; Zamarchi R
Clin Cancer Res; 2010 Nov; 16(21):5233-43. PubMed ID: 20978147
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
[TBL] [Abstract][Full Text] [Related]
37. The myelodysplastic syndromes.
Nguyen PL
Hematol Oncol Clin North Am; 2009 Aug; 23(4):675-91. PubMed ID: 19577164
[TBL] [Abstract][Full Text] [Related]
38. [A feature of hematological findings in myelodysplastic syndromes].
Bando S; Niiya T; Murase M; Makino H
Rinsho Byori; 1998 Aug; 46(8):790-5. PubMed ID: 9760831
[TBL] [Abstract][Full Text] [Related]
39. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
[TBL] [Abstract][Full Text] [Related]
40. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes.
Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
Int J Hematol; 1993 Aug; 58(1-2):53-61. PubMed ID: 8219112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
